Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia

British Journal of Haematology

Volumn 112, Issue 2, 2001, Pages 308-314

  Karászi, Éva ^a   Jakab, Katalin ^b   Homolya, László ^c   Szakács, Gergely ^c   Holló, Zsolt ^b   Telek, Béla ^a   Kiss, Attila ^a   Rejtô, László ^a   Nahajevszky, Sarolta ^b   Sarkadi, Balázs ^b,c   Kappelmayer, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b National Institute of Haematology and Immunology Budapest   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Acute myeloid leukaemia; Calcein AM; P glycoprotein; Verapamil

Indexed keywords

ANTHRACYCLINE; CALCEIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUNGARY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST; TREATMENT FAILURE;

ACUTE DISEASE; BONE MARROW CELLS; CELLS, CULTURED; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUORESCEINS; FLUORESCENT DYES; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID; LEUKOCYTES; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0035120672     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02554.x     Document Type: Article

References (41)

1. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantron, etoposide, and cytarabine (PSC-MEC)
2. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
3. Coexpression of multidrug resistance involve proteins: A flow cytometric analysis
4. Clinical relevance of transmembrane drug efflux as mechanism of multidrug resistance
5. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques
6. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
7. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukaemia
8. Mechanism of drug resistance in hematologic malignancies
9. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukaemia
10. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia
11. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry
12. Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukaemia: Impact of antibodies, sample source and disease status
13. The MDR phenotype in hematologic malignancies: Prognostic relevance and future perspectives
14. Calcein accumulation as a fluorometric functional assay of the multidrug transporter
15. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells
16. Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1
17. Fluorescent cellular indicators are extruded by the multidrug resistance protein
18. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells
19. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: A method validated by the laboratories of the French drug resistance network
20. Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment
21. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: Results of molecular and functional assays, and correlation with treatment outcome
22. Multidrug resistance: Clinical relevance in solid tumours and strategies for circumvention
23. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamin 123 efflux assay
24. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
25. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
26. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR
27. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
28. MDR/P-glycoprotein in hematological neoplasms
29. Functional expression of MDR-1 in acute myeloid leukemia: Correlation with clinical-biological, immunophenotypical and prognostic disease characteristic
30. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia
31. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia
32. 2 is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux
33. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers
34. Multidrug resistance-associated protein (MRP) in hematological malignancies
35. P-glycoprotein expression in patients with acute leukemia - Clinical relevance
36. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
37. Consensus protocol for the flow cytometric immunophenotyping of hemopoietic malignancies
38. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
39. Diagnostics of multidrug resistance in cancer
40. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay
41. Expression of multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukaemia: Absence of correlation with response to treatment